Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$6.48 USD
-0.21 (-3.14%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.47 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 41 - 60 ( 366 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dosing Starts in Phase 2 Trial of DNA COVID-19 Vaccine; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-3107 Phase 1/2 Trial Dosing Initiation; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-5401 Favorable 18-Month Brain Cancer Survival Data; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PFE and MRNA COVID-19 Vaccine Interims Are Strong, More Competition Coming
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PFE and MRNA COVID-19 Vaccine Interims Are Strong, More Competition Coming
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 DNA Vaccine Phase 2 Trial Initiated; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: 3100 Phase 3 Data Now in 1H21, 5401 Data at SNO, Upgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Partial Hold Imposed on Planned COVID-19 Vaccine Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2/3 Clinical Hold Costs Precious Time Given Competition - PT to $8
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vaccine Manufacturing Capacity Strengthened; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Years of Cash, Not Expecting INO-4800 to Pan Out Against Competition
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-4800 Protects Primates in COVID-19 Challenge Study; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Orphan Drug Designation Granted to INO-3107; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R